Filing Flows › Health Care › Entera Bio (ENTX)
Entera Bio (ENTX) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 9, 2025 · Entera Bio (ENTX) Q1 2025 earnings results →
Entera Bio made $42K in Q1 2025. Operating margin n/m, net loss $2.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 9, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $42K in Q1 2025, down 49% from the previous quarter.
Operating costs exceeded revenue by $2.6M, an operating margin of -6102.4%. The quarter ended with a net loss of $2.6M, wider than the previous quarter's $2.4M loss.
Operating cash flow was −$1.4M. Non-cash charges added back $8K of depreciation and $604K of share-based compensation. Working capital and other items added $551K. Capital expenditures of $8K exceeded it, leaving free cash flow of −$1.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 9, 2025 | $42K | — | n/m | −$2.6M | −$1.4M |
| Q4 2024 | 10-K | Mar 28, 2025 | $82K | — | n/m | −$2.4M | −$1.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Entera Bio
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet for osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n = 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD).
In its own words, from its 8-K, filed Aug 7, 2026.
Entera Bio against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ENTX Entera Bio | Q1 2025 | $42K | — | n/m |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Entera Bio 10-Q on SEC EDGAR · CIK 1638097 · Biological Products, (No Diagnostic Substances)
More on ENTX
History
Every quarter: Q1 2025 results · Q4 2024 results